Role of Biomarkers in FLT3 AML

Cancers

Jiao Wei¹  Nitika¹  Ai-Min Hui¹ 

[1] Fosun Pharma USA Inc., Boston, MA 02421, USA;

关键词: acute myeloid leukemia;    FLT3 inhibitors;    FLT3-ITD;    FLT3-TKD;    biomarkers;    resistance;   

DOI  :  10.3390/cancers14051164

来源: DOAJ

【 摘 要 】

Acute myeloid leukemia is a disease characterized by uncontrolled proliferation of clonal myeloid blast cells that are incapable of maturation to leukocytes. AML is the most common leukemia in adults and remains a highly fatal disease with a five-year survival rate of 24%. More than 50% of AML patients have mutations in the FLT3 gene, rendering FLT3 an attractive target for small-molecule inhibition. Currently, there are several FLT3 inhibitors in the clinic, and others remain in clinical trials. However, these inhibitors face challenges due to lack of efficacy against several FLT3 mutants. Therefore, the identification of biomarkers is vital to stratify AML patients and target AML patient population with a particular FLT3 mutation. Additionally, there is an unmet need to identify alternative approaches to combat the resistance to FLT3 inhibitors. Here, we summarize the current knowledge on the utilization of diagnostic, prognostic, predictive, and pharmacodynamic biomarkers for FLT3-mutated AML. The resistance mechanisms to various FLT3 inhibitors and alternative approaches to combat this resistance are also discussed and presented.

【 授权许可】

Unknown